Based on the Nautilus Biotechnology Inc stock forecast from 2 analysts, the average analyst target price for Nautilus Biotechnology Inc is USD 3.38 over the next 12 months. Nautilus Biotechnology Inc’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Nautilus Biotechnology Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Nautilus Biotechnology Inc’s stock price was USD 1.54. Nautilus Biotechnology Inc’s stock price has changed by -9.94% over the past week, -23.00% over the past month and -45.20% over the last year.
No recent analyst target price found for Nautilus Biotechnology Inc
No recent average analyst rating found for Nautilus Biotechnology Inc
Company Overview Nautilus Biotechnology Inc
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. Read Less
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution compris...Read More
Frequently Asked Questions About Nautilus Biotechnology Inc (NAUT) Stock
Based on ratings from 2 analysts Nautilus Biotechnology Inc's stock is Under-perform. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, 1 sell and 1 hold ratings.
Unfortunately we do not have enough data on NAUT's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for NAUT is USD 3.38 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 1.75.
Unfortunately we do not have enough data on NAUT's stock to indicate if its overvalued.
The last closing price of NAUT's stock was USD 1.54.
The most recent market capitalization for NAUT is USD 0.20B.
Based on targets from 2 analysts, the average taret price for NAUT is projected at USD 3.38 over the next 12 months.
This means that NAUT's stock price may go up by +119.16% over the next 12 months.
We can't find any ETFs which contains Nautilus Biotechnology Inc's stock.
As per our most recent records Nautilus Biotechnology Inc has 161 Employees.
Nautilus Biotechnology Inc's registered address is 2701 Eastlake Avenue East, Seattle, WA, United States, 98102.
You can get more information about it from Nautilus Biotechnology Inc's website at https://www.nautilus.bio.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Nautilus Biotechnology Inc (NAUT) Stock
Based on ratings from 2 analysts Nautilus Biotechnology Inc's stock is Under-perform. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, 1 sell and 1 hold ratings.
Unfortunately we do not have enough data on NAUT's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for NAUT is USD 3.38 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 1.75.
Unfortunately we do not have enough data on NAUT's stock to indicate if its overvalued.
The last closing price of NAUT's stock was USD 1.54.
The most recent market capitalization for NAUT is USD 0.20B.
Based on targets from 2 analysts, the average taret price for NAUT is projected at USD 3.38 over the next 12 months.
This means that NAUT's stock price may go up by +119.16% over the next 12 months.
We can't find any ETFs which contains Nautilus Biotechnology Inc's stock.
As per our most recent records Nautilus Biotechnology Inc has 161 Employees.
Nautilus Biotechnology Inc's registered address is 2701 Eastlake Avenue East, Seattle, WA, United States, 98102.
You can get more information about it from Nautilus Biotechnology Inc's website at https://www.nautilus.bio.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NAUT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
